CureVac.
biopharmaceutical company in Germany
- Reports this week
- 0
- Active events
- 0
- Connections
- 36
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.Well supported4 reports1 development inside
-
CureVac operates sites in the Netherlands, Belgium, Switzerland, and the U.S. (including Boston).Speculative1 report
-
GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.Some support1 report1 development inside
-
GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.Some support1 report
-
CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.Some support1 report1 development inside
No events began in the chosen period. Widen it, or reset.
Around CureVac this week
News at the entities that move CureVac most-
FDA StructuralThe FDA's authorization decision sparked criticism from the American Lung Association, which was also involved in a public statement via Thomas Carr.Moves CureVac
-
GSK OperationalEmma Walmsley, formerly of GSK, has been named CEO of HP Inc. to steer the company through the chip shortage.Moves CureVac
-
Pfizer OperationalPfizer paid for the CD228V license.Moves CureVac
-
CRISPR Therapeutics Mentioned togetherCRISPR Therapeutics presented clinical data at the American Society of Hematology meeting on November 4, 2026.Moves CureVac
-
Boston Shared contextA new musical premiered in Boston, featuring Amy Cole and Conor Sullivan.Moves CureVac
-
MarketBeat Mentioned togetherCitigroup and Benchmark issued buy ratings for Strategy shares, while MarketBeat reported the consensus rating for the stock.Moves CureVac
Connections
The 7 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BioNTech Structural
BioNTech acquired CureVac, making it a wholly owned subsidiary to strengthen its mRNA cancer immunotherapy portfolio.
-
GSK Operational
CureVac and GSK have established an operational partnership involving the sale of vaccine rights and shared involvement in legal disputes.
-
FDA Structural
FDA formally regulates and grants clearance for CureVac's clinical trials and IND applications.
-
Pfizer Operational
The companies are actively competing and engaged in legal disputes over mRNA vaccine patents.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports on CureVac's analyst ratings and company developments.
-
CRISPR Therapeutics Mentioned together
Both companies are co-mentioned as operating within the biopharmaceutical healthcare sector.
-
Boston Shared context
CureVac operates and maintains a business presence within the city of Boston.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
1 eventShow 1 earlier month
June 2026
5 events- BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.
- CureVac operates sites in the Netherlands, Belgium, Switzerland, and the U.S. (including Boston).
- GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.
- GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.
- CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.